P
Paratus Sciences
Improving human health and health security through the study of bat biology
About Paratus Sciences
Paratus Sciences is a biotech startup that aims to improve human health and health security by studying bat biology. The company believes that bats, despite their misunderstood reputation, possess unique physiological traits that could potentially be harnessed for therapeutic purposes. These traits include the ability to control inflammation, tolerate viral infection, resist cancer, adapt to extreme diets, and live exceptionally long lives relative to their size.
Paratus Sciences operates in the biotechnology market, specifically in the field of therapeutic discovery. The company's business model revolves around identifying and developing potential therapeutics for various diseases by unlocking the secrets of the bat genome. To achieve this, Paratus employs a comparative biology approach, utilizing bioinformatics, machine learning, protein structure prediction, protein-protein interaction mapping, and bat antibody libraries.
The company's clients are likely to be in the healthcare and pharmaceutical industries, who would be interested in the therapeutics developed from the bat genome. Paratus Sciences generates revenue by developing and potentially licensing these therapeutics to healthcare and pharmaceutical companies for further development and commercialization.
In summary, Paratus Sciences is a unique player in the biotech industry, leveraging the untapped potential of bat biology to develop innovative therapeutics that could revolutionize healthcare.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- New York City, United States
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 71.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Feb 2023 | $100M | $400M | EcoR1 Capital · Leaps by Bayer · Polaris Partners · ARCH Venture Partners | ↗ |
| SPINOUTOther financing | Jan 2021 | $0 | — | Massachusetts Institute of Technology · National University of Singapore | — |
Growth signals
Latest recorded traffic for Paratus Sciences is 1.6K monthly website visits, down 11.1% over the last three months. Paratus Sciences's team grew 17.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
EcoR1 Capital
Leaps by Bayer
Polaris Partners
ARCH Venture Partners
ClavystBio
Other known investors2 additional known investors
Massachusetts Institute of Technology
National University of Singapore
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Paratus Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Paratus Sciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.